SSBP2 is downregulated in several malignancies, such as esophageal squamous cell carcinoma, prostate cancer, and acute myeloid leukemia, and in previous studies, it has been speculated that promoter methylation may be the main mechanism of loss of SSBP2 expression. Here, SSBP2 is linked to prostate carcinoma.